{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T09:09:15Z","timestamp":1751879355787,"version":"3.40.5"},"reference-count":55,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clinthera.2024.08.008","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T11:41:29Z","timestamp":1725968489000},"page":"e1-e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Budget Impact Analysis of Dapagliflozin in Treating Patients With Heart Failure With Reduced Ejection Fraction From the Perspective of Malaysian Public Healthcare System"],"prefix":"10.1016","volume":"46","author":[{"given":"Yi Jing","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo Zheng","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9750-9588","authenticated-orcid":false,"given":"Siew Chin","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.08.008_bib0001","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.carpath.2011.11.007","article-title":"The pathophysiology of heart failure","volume":"21","author":"Kemp","year":"2012","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0002","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11886-021-01588-y","article-title":"Improving quality of life in heart failure","volume":"23","author":"Freedland","year":"2021","journal-title":"Curr Cardiol Rep"},{"year":"2020","series-title":"Global Burden of Disease Study 2019 (GBD 2019)","key":"10.1016\/j.clinthera.2024.08.008_bib0003"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0004","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijcard.2013.12.028","article-title":"The annual global economic burden of heart failure","volume":"171","author":"Cook","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0005","unstructured":"National Institutes of Health, Ministry of Health Malaysia. National Health and Morbidity Survey 2019 non-communicable diseases, healthcare demand, and health literacy\u2014key findings. 2020. Accessed December 9, 2022. https:\/\/iku.gov.my\/nhms-2019."},{"key":"10.1016\/j.clinthera.2024.08.008_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0288035","article-title":"Financial burden of heart failure in Malaysia: a perspective from the public healthcare system","volume":"18","author":"Ong","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0007","doi-asserted-by":"crossref","first-page":"971592","DOI":"10.3389\/fcvm.2022.971592","article-title":"Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study","volume":"9","author":"Ong","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0008","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.hlpt.2019.01.002","article-title":"Registry based analysis of cost-of-illness study among stage C heart failure patients at Hospital Queen Elizabeth II, Sabah, Malaysia","volume":"8","author":"Shafie","year":"2019","journal-title":"Health Policy Technol"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0009","article-title":"Multimorbidity in patients with heart failure from 11 Asian regions: a prospective cohort study using the ASIAN-HF registry","volume":"15","author":"Tromp","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0010","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1093\/eurheartj\/ehw331","article-title":"Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry","volume":"37","author":"Lam","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0011","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5334\/gh.1108","article-title":"Trends for readmission and mortality after heart failure hospitalisation in Malaysia, 2007 to 2016","volume":"17","author":"Lim","year":"2022","journal-title":"Glob Heart"},{"issue":"2","key":"10.1016\/j.clinthera.2024.08.008_bib0012","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ehf2.14608","article-title":"Characteristics of patients admitted with heart failure: insights from the first Malaysian Heart Failure Registry","volume":"11","author":"Wan Ahmad","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"17","key":"10.1016\/j.clinthera.2024.08.008_bib0013","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0014","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijcard.2021.10.060","article-title":"Treatment pattern amongst hospitalized HF patients stratified by EF subgroups: interim review of National Malaysian Heart Failure (MYHF) Registry","volume":"345","author":"Ghazi","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0015","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/eurjhf\/hfq219","article-title":"Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology","volume":"13","author":"Lainscak","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0018","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"37","key":"10.1016\/j.clinthera.2024.08.008_bib56","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0019","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.clinthera.2024.08.008_bib0021","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40258-023-00825-5","article-title":"Is using sodium-glucose cotransporter-2 inhibitors to treat adults with chronic heart failure cost-effective? A systematic review of cost-effectiveness studies","volume":"21","author":"Tan","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"issue":"7","key":"10.1016\/j.clinthera.2024.08.008_bib0022","doi-asserted-by":"crossref","first-page":"e2114501","DOI":"10.1001\/jamanetworkopen.2021.14501","article-title":"Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"Isaza","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0023","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12933-021-01387-3","article-title":"Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia\u2013Pacific region","volume":"20","author":"Liao","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0024","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ejhf.1978","article-title":"Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF","volume":"22","author":"McEwan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0025","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jamacardio.2021.1437","article-title":"Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction","volume":"6","author":"Parizo","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0026","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1177\/2047487320938272","article-title":"Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective","volume":"28","author":"Savira","year":"2021","journal-title":"Eur J Prevent Cardiol"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0027","doi-asserted-by":"crossref","first-page":"733681","DOI":"10.3389\/fphar.2021.733681","article-title":"Cost-effectiveness of adding SGLT2 inhibitors to standard treatment for heart failure with reduced ejection fraction patients in China","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0028","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijcard.2020.08.017","article-title":"Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction","volume":"322","author":"Krittayaphong","year":"2021","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.clinthera.2024.08.008_bib0029","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1002\/ehf2.12844","article-title":"Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China","volume":"7","author":"Yao","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0030","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/14737167.2022.1997595","article-title":"Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia","volume":"22","author":"Gil-Rojas","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0031","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/13696998.2022.2054226","article-title":"Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt","volume":"25","author":"Abdelhamid","year":"2022","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0032","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1002\/ehf2.13583","article-title":"Cost-utility analysis of add-on dapagliflozin in heart failure with reduced ejection fraction in the Philippines","volume":"8","author":"Mendoza","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0033","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"year":"2019","series-title":"Pharmacoeconomic Guidelines for Malaysia, 2019","key":"10.1016\/j.clinthera.2024.08.008_sbref0034"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0035","unstructured":"National Pharmaceutical Regulatory Agency. Forxiga (dapagliflozin) [package insert]. Accessed July 1, 2022. https:\/\/quest3plus.bpfk.gov.my\/pmo2\/detail.php?type=product&id=MAL14015014A."},{"year":"2019","series-title":"Clinical Practice Guidelines\u2014Management of Heart Failure 2019","key":"10.1016\/j.clinthera.2024.08.008_sbref0036"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0037","unstructured":"Department of Statistics Malaysia. Current population estimates, Malaysia 2022 Accessed October 10, 2022. https:\/\/www.dosm.gov.my\/v1\/index.php?r=column\/cthemeByCat&cat=155&bul_id=dTZXanV6UUdyUEQ0SHNWOVhpSXNMUT09&menu_id=L0pheU43NWJwRWVSZklWdzQ4TlhUUT09."},{"key":"10.1016\/j.clinthera.2024.08.008_bib0038","unstructured":"Population division of the Department of Economic and Social Affairs of the United Nations Secretariat. Malaysia population 2022 (demographics, maps, graphs). Accessed October 10, 2022. https:\/\/worldpopulationreview.com\/countries\/malaysia-population."},{"key":"10.1016\/j.clinthera.2024.08.008_bib0039","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijcard.2021.10.040","article-title":"Demographic characteristics differences across EF subgroups in the Malaysian Heart Failure (MYHF) Registry","volume":"345","author":"Abidin","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0040","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/eurjpc\/zwaa147","article-title":"Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017","volume":"28","author":"Bragazzi","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0041","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijcard.2021.10.057","article-title":"Demographic and characteristic of patients admitted with heart failure: interim analysis of Malaysia Heart Failure (MYHF) Registry","volume":"345","author":"Wan Ahmad","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0042","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijcard.2021.10.055","article-title":"Malaysian Heart Failure (MYHF) Registry substantiates high burden of comorbidities across the continuum of ejection fraction in Malaysian HF patients","volume":"345","author":"Henry","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0043","unstructured":"Pharmaceutical Services Programme, Ministry of Health Malaysia. Formulari Ubat KKM (FUKKM). Accessed September 23, 2022. https:\/\/www.pharmacy.gov.my\/v2\/en\/apps\/fukkm."},{"key":"10.1016\/j.clinthera.2024.08.008_bib0044","first-page":"A33","article-title":"38 Impact of SGLT2 inhibitors on diuretic requirement and renal function in a routine community heart failure population","volume":"108","author":"Doyle","year":"2022","journal-title":"Heart"},{"issue":"4, Suppl","key":"10.1016\/j.clinthera.2024.08.008_bib0045","doi-asserted-by":"crossref","first-page":"S340","DOI":"10.1016\/j.healun.2022.01.1405","article-title":"Change in diuretic dose after initiation of a SGLT2 inhibitor in patients with heart failure with reduced ejection fraction","volume":"41","author":"Wildemann","year":"2022","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.clinthera.2024.08.008_bib0046","doi-asserted-by":"crossref","first-page":"183","DOI":"10.36628\/ijhf.2022.0009","article-title":"Effects of empagliflozin on diuretics reduction in outpatient heart failure patients","volume":"4","author":"Kim","year":"2022","journal-title":"Int J Heart Fail"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0047","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0048","unstructured":"Department of Statistics Malaysia. Consumer Price Index, Malaysia, 2022 Accessed February 20, 2022. https:\/\/www.dosm.gov.my\/v1\/index.php?r=column\/cthemeByCat&cat=106&bul_id=MWsxc25MWVgyK3JrTjdqU1VRTXpIUT09&menu_id=bThzTHQxN1ZqMVF6a2I4RkZoNDFkQT09."},{"key":"10.1016\/j.clinthera.2024.08.008_bib0049","unstructured":"Central Bank of Malaysia. Ringgit foreign exchange rates, 2023 Accessed February 20, 2022. https:\/\/www.bnm.gov.my\/web\/guest\/exchange-rates."},{"key":"10.1016\/j.clinthera.2024.08.008_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000236","article-title":"Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis","volume":"7","author":"Clarke","year":"2010","journal-title":"PLOS Medicine"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0051","first-page":"271","article-title":"What are the direct medical costs of managing Type 2 diabetes mellitus in Malaysia?","volume":"72","author":"Feisul","year":"2017","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0052","unstructured":"Attorney General's Chambers of Malaysia. Federal Government Gazette, Fees (medical) (cost of services) Order 2014. Accessed October 10, 2022. https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjpnsS499P6AhUx1zgGHc3kCi4QFnoECBIQAQ&url=https\/3A\/2F\/2Fwww.moh.gov.my\/2Findex.php\/2Fdatabase_stores\/2Fattach_download\/2F387\/2F257&usg=AOvVaw1JDDpVpha9u9B7B_9J0kzG."},{"key":"10.1016\/j.clinthera.2024.08.008_bib0053","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jval.2021.04.374","article-title":"PCV34 cost-offset analysis of dapagliflozin in treating heart failure with reduced ejection fraction (HFREF) in China","volume":"24","author":"Guan","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2024.08.008_bib0054","unstructured":"Aon. The Global Medical Trend Rates Report 2023. Accessed April 12, 2023. https:\/\/www.aon.com\/getmedia\/01fefa12-0ca6-4d5a-8754-cf8691bcc19b\/global-medical-trend-rates-report.pdf."},{"key":"10.1016\/j.clinthera.2024.08.008_bib0055","unstructured":"Department of Statistics Malaysia. Consumer Price Index, Malaysia 2023 Accessed April 12, 2023. https:\/\/www.dosm.gov.my\/v1\/index.php?r=column\/cthemeByCat&cat=106&bul_id=anQxdFdodnVXOWY4Zi8xZ2NTbllDUT09&menu_id=bThzTHQxN1ZqMVF6a2I4RkZoNDFkQT09."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T01:02:56Z","timestamp":1732410176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0149291824002170"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.08.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Budget Impact Analysis of Dapagliflozin in Treating Patients With Heart Failure With Reduced Ejection Fraction From the Perspective of Malaysian Public Healthcare System","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}